



## ASX ANNOUNCEMENT

24 August 2020

### IDT Makes a Submission to Australian Government COVID-19 Request for Information

---

**IDT Australia Limited (ASX: IDT)** provides the following update: The Company has made a formal submission to the Australian Government's COVID-19 Vaccine and Treatment Manufacture and Supply Chain Request For Information (RFI).

The Government is conducting an audit of onshore capacity and capability to complement existing information and help inform possible COVID-19 vaccine and treatment manufacturing scenarios. This RFI seeks information regarding COVID-19 vaccine and treatment manufacture and supply, in particular, manufacturer current capability and capacity, as well as manufacturer willingness to expand, modify or repurpose capability and capacity to support at population-scale the manufacture of COVID-19 vaccines and treatments.<sup>1</sup>

IDT's submission to the RFI contains details of the Company's current facilities and capabilities as well as our future potential capacity in relation to the possible manufacture and supply of COVID-19 vaccines and treatments. Highlights of IDT's current and potential COVID-19 vaccine and treatment capabilities include:

- Sterile vial fill/finish of liquid and lyophilised products;
- Bulk liquid formulation;
- Cold chain management and storage (cGMP);
- Solid oral dose form manufacture (tablet / capsule);
- Manufacture of Active Pharmaceutical Ingredients (APIs) and excipients;
- Process and analytical method development; and
- In-house analytical and microbiological testing.

IDT's manufacturing site is located in Melbourne's southern pharmaceutical manufacturing hub, approximately 25 kilometres east of the Melbourne CBD. Within the site there is ample capacity to expand and extend IDT's current operations. There are a number of facilities which could be repurposed to accommodate additional pharmaceutical production if required. Unlike a

---

<sup>1</sup> <https://www.tenders.gov.au/Atm/Show/82b3fd6b-efdd-42f9-a4df-6388e0d047e4>

#### About IDT

IDT (ASX:IDT) is an Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. The Company has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT's facilities are cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.



greenfield site, IDT's facilities are all housed within the Company's established and accredited Quality System and cGMP accreditation.

"IDT has already been involved in the Government's response during the initial phase of the COVID-19 crisis." said IDT's CEO Dr David Sparling. "IDT has made a submission to this RFI because we want to continue to play a role in Australia's COVID-19 response and we believe that the Company is well placed to potentially assist with COVID-19 vaccine and treatment projects."

The Company has API and solid oral dosage form manufacturing capabilities which could be tasked with manufacturing a range of COVID-19 treatments or supportive therapies. IDT's API facilities and chemistry experience could also produce excipients and buffers required for sterile finished dosage form manufacturing. In addition, IDT has a sterile manufacturing facility with lyophilisation capabilities which could potentially be utilised to manufacture COVID-19 vaccines.

Ends..../

## **IDT**

Authorised by the Board of Directors of IDT Australia Limited. For further information please contact:

Dr David Sparling

Chief Executive Officer - IDT Australia Limited

+61 3 9801 8888

### **About IDT**

IDT (ASX:IDT) is an Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. The Company has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT's facilities are cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.